Yihan Li
Stock Analyst at Barclays
(2.63)
# 2,976
Out of 4,707 analysts
43
Total ratings
75%
Success rate
10.3%
Average return
Main Sectors:
Stocks Rated by Yihan Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: IPN Ipsen S.A. | Downgraded: Sell | €170.00 → €155.00 | €159.20 | -2.64% | 14 | Sep 8, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $66 → $51 | $46.61 | +10.00% | 3 | Sep 8, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 155.00 | CHF 162.70 | -4.73% | 21 | Dec 8, 2025 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 375.00 | kr 292.00 | +28.42% | 2 | Nov 28, 2025 | |
| SWX: ROP Roche Holding AG | Maintained: Hold | CHF 275.00 | CHF 350.50 | -21.54% | 3 | Oct 24, 2025 |
Ipsen S.A.
Sep 8, 2026
Downgraded: Sell
Price Target: €170.00 → €155.00
Current: €159.20
Upside: -2.64%
Zealand Pharma A/S
Sep 8, 2026
Downgraded: Hold
Price Target: $66 → $51
Current: $46.61
Upside: +10.00%
Galderma Group AG
Dec 8, 2025
Maintained: Buy
Price Target: CHF 155.00
Current: CHF 162.70
Upside: -4.73%
Novo Nordisk A/S
Nov 28, 2025
Maintained: Hold
Price Target: kr 375.00
Current: kr 292.00
Upside: +28.42%
Roche Holding AG
Oct 24, 2025
Maintained: Hold
Price Target: CHF 275.00
Current: CHF 350.50
Upside: -21.54%